Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
|Articles|June 18, 2020
Pharmacy Industry Outlook for Technicians
Experts discuss insights from NHA's 2019 Industry Outlook research from employers of pharmacy technicians to better understanding their needs and the value of certification for this role.
Advertisement
During episode 3, host Jeremy Sasser and co-host Jessica Langley, executive director for education and advocacy at NHA, share insights from NHA's 2019 Industry Outlook research,
Advertisement
Related to this article
The most enduring resources a preceptor can give students are the confidence and tools to ask deeper questions.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
ENDURANCE trial finds fixed 2-year lenalidomide maintenance matches continuous therapy for standard-risk multiple myeloma survival, guiding oncology pharmacists on MM regimen toxicity.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
Oncology Pharmacists Reduce Adverse Drug Reactions in Hematologic Cancer Care
4
Fall 2026 Quiz: Test Your Pharmacy Knowledge!
5